Vor Biopharma Inc. Common Stock
Compare this stock
VOR Stock Report Card
$
14%
Performance
Score:
10/100
VOR returned -61.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Technicals
Score:
10/100
VOR receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
Earnings
Score:
10/100
VOR has missed earnings 6 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 16 quarters, VOR has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
43/100
VOR has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.
Vor Biopharma Inc. Common Stock Summary
Nasdaq / VOR
Healthcare
Biotechnology
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
VOR scored poorly on our reportcard. Here are some similar companies and how they performed.
